Core Quantum Technologies

Ohio State University

Core Quantum Technologies develops micelle-encapsulated nanocrystals that provide unblinking and long-lasting insight into nanoscale activity. Improving the quality of your data, so you can improve the quality of human life. By aggregating several quantum dots into a protective polymer envelope, MultiDots provide a brighter, longer-lasting signal with sharp peaks that wipe the ambiguity out of your research. Now imagine all that with magnetic capabilities—allowing you to concurrently observe and manipulate analytes.  We wanted to create a reliable probe that could stand up to the rigors of the lab and produce a fuller, sharper picture of biological interactions over time. Encouraged by their brightness and general durability, we’ve been convinced that the nanocrystals in quantum dots held the key. Core Quantum Technologies was founded to overcome the technology’s inherent limitations. And we have. Our micelle-encapsulated nanocrystals provide unblinking and long-lasting insight into nanoscale activity. Improving the quality of your data, so you can improve the quality of human life.


Jessica Winter, Cofounder and Chief Scientific Officer, is a Professor in the William G. Lowrie Department of Chemical and Biomolecular Engineering and the Department of Biomedical Engineering, Associate Director of the MRSEC Center for Emergent Materials at the Ohio State University, and appointee to the Chemical Engineering Technical Operating Council of the American Institute of Chemical Engineers. She received her PhD in Chemical Engineering from the University of Texas at Austin in 2004, and completed a postdoctoral fellowship at the Center for Innovative Visual Rehabilitation at the Boston VA Hospital in 2006. Her research interests include nanoparticles for cancer imaging, diagnostics, and drug delivery; and cell migration in the brain tumor microenvironment. She is a co-founder and Chief Scientific Officer of Core Quantum Technologies, a company commercializing nanoparticle reagents for leukemia diagnostics. She was named TechColumbus Innovator of the Year, Columbus Business First 40 under 40, and Columbus Business First 20 People to Know in Technology. In addition, she has received the American Chemical Society Rising Star Award and the Golden Mouse Trap Engineering Rising Star Award; she was named to Top 25 STEM professors in Ohio; and is a fellow of the AAAS, AIMBE, and senior member of the IEEE and AIChE.

Kristie Melnik, CEO, has over 15 years of experience in translational science for magnetic cell separation, flow cytometry, and stem cell science. Melnik started a biotech services company, Cytolutions, in 2010. Under Cytolutions, Melnik lead four very successful projects, two of which became licensed technologies and two of which became companies. The first company, VetGraft, focuses on delivering stem cell and protein products to the equine market specific for osteoarthritic joints and soft tissue injuries. Melnik developed the pilot product in 2012, and transferred the knowledge to scale up manufacturing, including the implementation of human tissue banking standards to the veterinarian space. This permitted Melnik to transfer internal manufacturing SOPs to secure ISO certification for the company. Additionally, she has driven customer acquisition, starting with 6 key veterinarians in 2014 and expanding the usage base to 120 using veterinarians today. Sales started at $250 in August 2014 and are now projected to exceed $1.5 million in 2017. Through Cytolutions, Melnik has consulted for or been employed by CQT since 2012. She helped secure NSF SBIR funds and Tech Validation Start Up funding from the state of Ohio. Additionally, Melnik worked with GMT Capital to secure the first tranche investment for MultiDot prototype development. Melnik has worked closely with GMT Capital to secure the second round of funding for MultiDot commercialization to US clinical flow cytometry labs. Relevant to this application, under Cytolutions, Melnik developed a magnetic NP in 2011 that was licensed in its provisional form to ST Genetics in Navasota, TX for $2 million. That NP allows the sexed semen company to increase their productivity by 20 to 30% by magnetically removing dead and dying sperm in a 20 minute step.

Dr. Mythreyi Unni, Research Scientist, has more than five years of experience in nanoparticle synthesis. She received her PhD in Chemical and Biomolecular Engineering from University of Florida. At CQT, she manages and oversees the production laboratory and quality control.